Fecal transplant plus immunotherapy and chemotherapy for colon cancer with liver spread
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of fecal microbiota transplant (FMT), an immunotherapy drug (QL1706), a targeted therapy (bevacizumab), and chemotherapy (XELOX) as a first treatment for advanced colon cancer that has spread to the liver. The goal is to see if this mix can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colon cancer that has spread to the liver.
- You have not had any prior cancer treatment for this condition.
- You are between 18 and 75 years old.
- You are in generally good health (ECOG performance status 0 or 1).
- Your cancer is MSS-type (microsatellite stable) and not MSI-H or dMMR, and if your tumor has certain gene mutations, you may not qualify.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial tests a combination of fecal microbiota transplantation (FMT), immunotherapy, and chemotherapy as a first treatment for advanced non-small cell lung cancer that does not have a driver gene mutation. The goal is to see if adding FMT can help the immune system fight the cancer better.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests whether adding a fecal microbiota transplant (FMT) to standard first-line chemotherapy can help shrink or control advanced colorectal cancer that cannot be surgically removed. FMT is a procedure that introduces healthy donor bacteria into your gut to possibly boost your body's response to treatment.
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
Hear when a new Colon Cancer Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.